Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 7/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237639 | 0.84 | ALDH1A1 (0.57) | HDAC1 | |
| SCHEMBL9339143 | 0.82 | PLAU (0.54) | MEP1BNR1H4HDAC1MRGPRX4 | |
| SCHEMBL17346631 | 0.81 | CYP2D6 (0.48) | HDAC1 | |
| SCHEMBL19910574 | 0.79 | MEP1B (0.64) | MEP1BNR1H4FOLH1FNTAFNTB | |
| SCHEMBL8176056 | 0.78 | NR1H4 (0.52) | MEP1BNR1H4FOLH1MRGPRX4MMP13 | |
| SCHEMBL184425 | 0.78 | NR1H4 (0.61) | MEP1BNR1H4HDAC1FOLH1MMP13 | |
| SCHEMBL17346618 | 0.78 | CYP2D6 (0.45) | HDAC1 | |
| SCHEMBL3530258 | 0.76 | KMT2A (0.64) | MEP1BNR1H4HDAC1FOLH1MRGPRX4 | |
| SCHEMBL15600276 | 0.76 | NR1H4 (0.61) | MEP1BNR1H4FOLH1MRGPRX4 | |
| SCHEMBL17863560 | 0.76 | MAPT (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| US-20210340276-A1 | COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND | ASTELLAS PHARMA INC. (JP) | 2021-11-04 | — | — | US | disclosed |
| WO-2020145227-A1 | COMPLEX COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020145228-A1 | COMPLEX COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | MEP1B 384/4885NR1H4 1592/4885HDAC1 1924/4885 |
| US-20210340276-A1 | COMPLEX HAVING ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND | MUC1, SIGLEC7, CA14 | MEP1B 704/4885NR1H4 1741/4885HDAC1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.